Bioactive Lipids as Chronic Myeloid Leukemia’s Potential Biomarkers for Disease Progression and Response to Tyrosine Kinase Inhibitors

Bioactive Lipids as Chronic Myeloid Leukemia’s Potential Biomarkers for Disease Progression and Response to Tyrosine Kinase Inhibitors

Chronic myelogenous leukemia (CML) is a myeloproliferative neoplasm that expresses the Philadelphia chromosome and constitutively activated Bcr-Abl tyrosine kinase in hematopoietic progenitor cells. Bcr-Abl tyrosine-kinase inhibitors (TKI) do not definitively cure all CML patients. The efficacy of T...

Full description

Bibliographic Details
Main Authors: Felipe Campos de Almeida, Maria G. Berzoti-Coelho, Diana Mota Toro, Maira da Costa Cacemiro, Vitor Leonardo Bassan, Gabriel Dessotti Barretto, Pedro Manoel Marques Garibaldi, Leonardo Carvalho Palma, Lorena Lobo de Figueiredo-Pontes, Carlos Arterio Sorgi, Lucia Helena Faciolli, Luiz Gustavo Gardinassi, Fabíola Attié de Castro
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-04-01
Series:Frontiers in Immunology
Subjects:
chronic myeloid leukemia
bioactive lipids
tyrosine kinase inhibitors
pathogenesis and metabolomics
tyrosine kinasa inhibitor
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.840173/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.840173/full

Similar Items